TY - JOUR
T1 - Prevalence and prognostic value of atrial fibrillation in patients with cardiac sarcoidosis
AU - Fujimoto, Yudai
AU - Matsue, Yuya
AU - Maeda, Daichi
AU - Dotare, Taishi
AU - Sunayama, Tsutomu
AU - Iso, Takashi
AU - Nakamura, Yutaka
AU - Singh, Yu Suresvar
AU - Akama, Yuka
AU - Yoshioka, Kenji
AU - Kitai, Takeshi
AU - Naruse, Yoshihisa
AU - Taniguchi, Tatsunori
AU - Tanaka, Hidekazu
AU - Okumura, Takahiro
AU - Baba, Yuichi
AU - Nabeta, Takeru
AU - Minamino, Tohru
N1 - Publisher Copyright:
© 2023 The Author(s). Published by Oxford University Press on behalf of the European Society of Cardiology.
PY - 2023/9/1
Y1 - 2023/9/1
N2 - Aims: The prognostic value of the presence of atrial fibrillation (AF) in patients at the time of cardiac sarcoidosis (CS) diagnosis is unknown. This study aimed to investigate the association between AF at the time of CS diagnosis and patient prognosis. Methods and results: This study is a post-hoc analysis of Illustration of the Management and Prognosis of Japanese Patients with CS, a multicentre, retrospective observational study that evaluated the clinical characteristics and prognosis of patients with CS. The primary endpoint was the combined endpoint of all-cause death and hospitalization due to heart failure. After excluding patients with missing data about AF status, 445 patients (62 ± 11 years, 36% males) diagnosed with CS according to the Japanese current diagnostic guideline were analysed. Compared to patients without AF, patients with AF (n = 46, 10%) had higher levels of brain natriuretic peptide and a higher prevalence of heart failure hospitalizations. During a median follow-up period of 3.2 years (interquartile range, 1.7-5.8 years), 80 primary endpoints were observed. Kaplan-Meier curve analysis indicated that concomitant AF at the time of diagnosis was significantly associated with a high incidence of primary endpoints (log-rank P = 0.002). This association was retained after adjusting for known risk factors including log-transformed brain natriuretic peptide levels and left ventricular ejection fractions [hazard ratio, 1.96 (95% confidence interval, 1.05-3.65); P = 0.035]. Conclusion: The presence of AF at the time of CS diagnosis is associated with higher incidence of all-cause death and heart failure hospitalization.
AB - Aims: The prognostic value of the presence of atrial fibrillation (AF) in patients at the time of cardiac sarcoidosis (CS) diagnosis is unknown. This study aimed to investigate the association between AF at the time of CS diagnosis and patient prognosis. Methods and results: This study is a post-hoc analysis of Illustration of the Management and Prognosis of Japanese Patients with CS, a multicentre, retrospective observational study that evaluated the clinical characteristics and prognosis of patients with CS. The primary endpoint was the combined endpoint of all-cause death and hospitalization due to heart failure. After excluding patients with missing data about AF status, 445 patients (62 ± 11 years, 36% males) diagnosed with CS according to the Japanese current diagnostic guideline were analysed. Compared to patients without AF, patients with AF (n = 46, 10%) had higher levels of brain natriuretic peptide and a higher prevalence of heart failure hospitalizations. During a median follow-up period of 3.2 years (interquartile range, 1.7-5.8 years), 80 primary endpoints were observed. Kaplan-Meier curve analysis indicated that concomitant AF at the time of diagnosis was significantly associated with a high incidence of primary endpoints (log-rank P = 0.002). This association was retained after adjusting for known risk factors including log-transformed brain natriuretic peptide levels and left ventricular ejection fractions [hazard ratio, 1.96 (95% confidence interval, 1.05-3.65); P = 0.035]. Conclusion: The presence of AF at the time of CS diagnosis is associated with higher incidence of all-cause death and heart failure hospitalization.
KW - Atrial fibrillation
KW - Cardiac sarcoidosis
KW - Heart failure
KW - Mortality
KW - Prognosis
UR - https://www.scopus.com/pages/publications/85175570508
UR - https://www.scopus.com/pages/publications/85175570508#tab=citedBy
U2 - 10.1093/ehjopen/oead100
DO - 10.1093/ehjopen/oead100
M3 - Article
AN - SCOPUS:85175570508
SN - 2752-4191
VL - 3
JO - European Heart Journal Open
JF - European Heart Journal Open
IS - 5
M1 - oead100
ER -